Guillain-Barre syndrome with antibody to a ganglioside, N-acetylgalactosaminyl GD1a

Brain

Volumn 123, Issue 1, 2000, Pages 116-124

  Kaida, K ^a   Kusunoki, Susumu ^b   Kamakura, K ^a   Motoyoshi, K ^a   Kanazawa, I ^b  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Anti ganglioside antibody; GalNAc GD1a; Guillain Barre syndrome; Motor axonal variant; Pure motor variant

Indexed keywords

GANGLIOSIDE ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CRANIAL NERVE; ELECTROPHYSIOLOGY; FACIAL NERVE PARALYSIS; FEMALE; GASTROINTESTINAL INFECTION; GUILLAIN BARRE SYNDROME; HUMAN; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 0033973335     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/123.1.116     Document Type: Article

References (33)

1. Alam TA, Chaudhry V, Cornblath DR. Electrophysiological studies in the Guillain-Barré syndrome: distinguishing subtypes by published criteria. Muscle Nerve 1998; 21: 1275-9.
2. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. [Review]. Ann Neurol 1990; 27 Suppl: S21-4.
3. Brown WF, Feasby TE, Hahn AF. Electrophysiological changes in the acute 'axonal' form of Guillain-Barré syndrome. Muscle Nerve 1993; 16: 200-5.
4. Cavanna B, Carpo M, Pedotti R, Scarpini E, Meucci N, Allaria S, et al. Anti-GM2 IgM antibodies: clinical correlates and reactivity with a human neuroblastoma cell line. J Neuroimmunol 1999; 94: 157-64.
5. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993; 43: 1911-7.
6. Cornblath DR. Electrophysiology in Guillain-Barré syndrome. [Review]. Ann Neurol 1990; 27Suppl: S17-20.
7. Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung H-P, Toyka KV, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 1998; 44: 780-8.
8. Hartung HP, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndrome - Part 1. [Review]. Muscle Nerve 1995; 18: 137-53.
9. Ho TW, Li CY, Cornblath DR, Gao CY, Asbury AK, Griffin JW, et al. Patterns of recovery in the Guillain-Barré syndromes. Neurology 1997; 48: 695-700.
10. Ihara Y, Saito K, Yoshimoto S, Hayabara T, Yuki N. Axonal Guillain-Barré syndrome associated with anti-GalNAc-GD1a antibody subsequent to Campylobacter jejuni (PEN 43) enteritis. [Japanese]. Rinsho Shinkeigaku 1995; 35: 901-3.
11. 4GalNacGC1a as antigens for monoclonal immunoglobulin M in neuropathy associated with gammopathy. J Biol Chem 1988; 263: 4369-73.
12. We S, Saito T, Nakamura K, Kanazawa N, Ogino M, Nukazawa T, et al. Association of anti-GM2 antibodies in Guillain-Barré syndrome with acute cytomegalovirus infection. J Neuroimmunol 1996; 68: 19-26.
13. Iwamori M, Sunada S, Ishihara E, Moki M, Fujimoto S, Nagai Y. Differential expression of fucosyl GM1 and a disialoganglioside with a NeuAc alpha 2-6GalNAc linkage (GD1e) in various rat ascites hepatoma cells. FEBS Lett 1986; 198: 66-70.
14. Jacobs BC, van Doom PA, Groeneveld JH, Tio-Gillen AP, van der Meché FG. Cytomegalovirus infections and anti-GM2 antibodies in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1997; 62: 641-3.
15. Khalili-Shirazi A, Gregson N, Gray I, Rees J, Winer J, Hughes R. Antiganglioside antibodies in Guillain-Barré syndrome after a recent cytomegalovirus infection. J Neurol Neurosurg Psychiatry 1999; 66: 376-9.
16. Kimura J. Electrodiagnosis in diseases of nerve and muscle, principles and practice. 2nd ed. Philadelphia: P.A. Davis; 1989.
17. Kornberg AJ, Pestronk A, Bieserk K, Ho TW, McKhann GM, Wu HS et al. The clinical correlates of high-titre IgG anti-GM1 antibodies. Ann Neurol 1994; 35: 234-7.
18. Kuroki S, Saida T, Nukina M, Haruta T, Yoshioka M, Kobayashi Y, et al. Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup19 and contain β-N-acetylglucosamine residues. Ann Neurol 1993; 33: 243-7.
19. Kusunoki S, Chiba A, Kon K, Ando S, Arisawa K, Tate A, et al. N-acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barré syndrome. Ann Neurol 1994; 35: 570-6.
20. Mond JJ, Lees A, Snapper CM. T cell-independent antigens type 2. [Review]. Annu Rev Immunol 1995; 13: 655-92.
21. Ogino M, Orazio N, Latov N. IgG anti-GM1 antibodies from patients with acute motor neuropathy are predominantly of the IgG1 and IgG3 subclasses. J Neuroimmunol 1995; 58: 77-80.
22. Ono M, Sakai T, Ohnishi A, Hashimoto T, Yuki N. Axonal Guillain-Barré syndrome associated with antibodies to GalNAc-GD1a and unidentified acidic glycolipids. [Japanese]. Rinsho Shinkeigaku 1997; 37: 119-22.
23. Papadea C, Check IJ. Human immunoglobulin G and immunoglobulin G subclasses: biochemical, genetic, and clinical aspects. [Review]. Crit Rev Clin Lab Sci 1989; 27: 27-58.
24. Parry GJ. Guillain-Barré syndrome. New York: Thieme Medical; 1993. p. 64-6.
25. Ropper AH, Wijdicks EFM, Truax BT. Guillain-Barré syndrome. Philadelphia: F.A.Davis; 1991. p. 107-8.
26. Tsuda N, Negoro K, Morimatsu M, Saito K, Yuki N. Guillain-Barré syndrome associated with anti-GalNAc-GD1a antibody subsequent to Campylobacter jejuni enteritis. [Japanese]. Rinsho Shinkeigaku 1995; 35: 208-10.
27. van der Meché FG, Schmitz PI, the Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326: 1123-9.
28. Visser LH, van der Meché FG, van Doom PA, Meulstee J, Jacobs BC, Oomes PG, et al. Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Brain 1995; 118: 841-7.
29. Visser LH, van der Meché FG, Meulstee J, Rothbarth PP, Jacobs BC, Schmitz PI, et al. Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Neurology 1996; 47: 668-73.
30. Willison HJ, Veitch J. Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller Fisher syndrome. J Neuroimmunol 1994; 50: 159-65.
31. Yuki N, Yoshino H, Sato S, Miyatake T. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 1990; 40: 1900-2.
32. Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K, et al. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med 1993; 178: 1771-5.
33. Yuki N, Taki T, Takahashi M, Saito K, Tai T, Miyatake T, et al. Penner's serotype 4 of Campylobacter jejuni has a lipopolysaccharide that bears a GM1 ganglioside epitope as well as one that bears a GD1a epitope. Infect Immun 1994; 62: 2101-3.